Abstract
Twenty patients with astrocytomas recurrent after surgery ± radiation were treated on a phase II protocol of the new anthracycline derivative menogaril 115 mg/m2 administered intravenously once per week. Sixteen patients were evaluable for treatment efficacy. No patient achieved a major therapeutic response. Three patients (19%) had stable disease for greater than 8 weeks, including one who showed minor evidence of tumor regression, but less than 50%. Thirteen patients failed. Treatment was well tolerated. One patient developed granulocytopenia, while none developed thrombocytopenia. Four patients required an interruption in their treatment for one to two weeks because of development of granulocytopenia (one patient) or other reasons. Other toxic effects included arm vein phlebitis and skin irritation, skin discoloration of the infused arm, mild to moderate nausea and vomiting, diarrhea, stomatitis, and a fatal central venous catheter infection. Despite the fact that menogaril appeared to have therapeutic activity against recurrent astrocytomas in our phase I studies, we could not document any activity in this phase II study.
Similar content being viewed by others
References
Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Cancer Treatment Reviews 16: 129–160, 1989
Stewart DJ: Human central nervous system pharmacology of antineoplastic agents: implications for the treatment of brain tumors. In: Chatel M, Darcel F, Pecker J, (eds) Brain Oncology, Biology, Diagnosis, and Therapy, Martinus Nijhoff Publishers, Dordrecht 387–395, 1987
McGovern JP, Nelson KD, Lassos M, Cradock JD, Plowman J, Christopher JP: Menogaril: A new anthracycline agent entering clinical trials. Invest New Drugs 2: 359–367, 1984
Stewart DJ, Maroon JA, Verma S, Perrault D, Earhart RH: Phase I study of weekly intravenous administration of menogaril to adults with solid tumors. American Journal of Clinical Oncology 12: 511–518, 1989
Stewart DJ, Verma S, Maroun JA, Robillard L, Earhart RH: Phase I study of oral menogaril administered on a once weekly schedule. Investigational New Drugs 8: 43–52, 1990
Eisenhauer E, Pritchard K, Perrault D, Verma S, Pater J: Phase II study of intravenous menogaril as first line chemotherapy for patients with breast cancer. Proc Am Soc Clin Oncol 6: 61, 1987
Stewart DJ, Verma S, Eisenhauer E, Pritchard K, Buckman R, Skillings J, Vandenberg T; NCI Canada phase II study of weekly oral menogaril as first line chemotherapy for recurrent breast cancer. Proc. Am Soc Clin Oncol 10: 74, 1991
Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47: 329–335, 1977
Mehta BM, Ebrahim SAD, Andrews D, Shapiro JR: Selection of BCNU-resistant cells with an over-representation of chromosomes 7 and 22 in primary and recurrent benign gliomas; a correlation between BCNU clinical resistance and a PDGF autocrine growth pathway. Proc Amer Assoc Cancer Res 29: 49, 1988
Spigelman MK, Zappulla RA, Strauchen JA, Feuer EJ, Johnson J, Goldsmith SJ, Malis LI, Holland JF: Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae. Cancer Res 46: 1453–1457, 1986
Stewart DJ: Intraarterial chemotherapy for brain tumors: a summary of the Ottawa experience. In: Chatel M, Darcel F, Pecker J, (eds) Brain Oncology, Biology, Diagnosis, and Therapy, Martinus Nijhoff Publishers, Dordrecht, 1987, 397–402.
Hoffman WF, Levin VA, Wilson CB: Evaluation of malignant glioma patients during the post-irradiation period. J Neurosurg 50: 624–628, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, D.J., Hugenholtz, H., DaSilva, V.F. et al. Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J Neuro-Oncol 13, 183–188 (1992). https://doi.org/10.1007/BF00172769
Issue Date:
DOI: https://doi.org/10.1007/BF00172769